Spectrum Pharmaceuticals Inc (SPPI)

Overview

Spectrum Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapies in oncology and hematology. The company, originally founded in 1987 as NeoTherapeutics, Inc., underwent a transformation in December 2002, adopting its current name to better reflect its focus on a broad range of spectrum in pharmacology, especially catering to cancer care. Based in Boston, Massachusetts, Spectrum Pharmaceuticals has established itself as a key player in addressing unmet medical needs through its cutting-edge research and strategic partnerships. Among its noteworthy collaborations are agreements with Hanmi Pharmaceutical Co. Ltd., The University of Texas M.D. Anderson Cancer Center, and ImmunGene, Inc., aimed at enhancing its research capabilities and expanding its product portfolio.

Products and Services

Spectrum Pharmaceuticals is at the forefront of innovation in cancer treatment, with a focus on developing products that offer new hope to patients battling cancer. Its pipeline includes:

• Eflapegrastim: A novel, long-acting granulocyte colony-stimulating factor designed to mitigate chemotherapy-induced neutropenia. Unlike traditional short-acting treatments, Eflapegrastim's extended activity aims to provide enhanced protection against infection by stimulating the body's production of white blood cells, thereby improving patients' quality of life during chemotherapy.
• Poziotinib: A cutting-edge irreversible tyrosine kinase inhibitor targeting non-small cell lung cancer (NSCLC) tumors harboring specific mutations. Poziotinib represents a significant advancement in personalized medicine, offering targeted therapy to patients with mutations that make their cancer resistant to other treatments. This focus on molecularly defined cancers underscores Spectrum Pharmaceuticals’ commitment to leading-edge cancer care.
• Anti-CD20-IFNa: An innovative antibody-interferon fusion molecule that marks a new frontier in cancer immunotherapy. Directed against CD20, a protein found on the surface of B cells, this compound is currently in Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including difficult-to-treat diffuse large B-cell lymphoma. The fusion of an antibody with interferon aims to harness the immune system's power more effectively, offering a promising new therapeutic avenue for lymphoma patients.